Patents by Inventor Yuzuru Ikehara

Yuzuru Ikehara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10408749
    Abstract: An imaging method includes: irradiating breast tissue with infrared light, detecting light in a narrow wavelength band selected from wavelength bands from 1400 nm or more to 1600 nm or less, among light radiated from the tissue irradiated with the infrared light, and generating, based on the detected light in the narrow wavelength band, an image to specify an area in the tissue containing breast cancer cell aggregation or breast cancer tissue.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 10, 2019
    Assignees: JAPAN ORGANIZATION OF OCCUPATIONAL HEALTH AND SAFETY, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, NIKON CORPORATION
    Inventors: Kenichi Harigaya, Daisuke Ozaki, Yuzuru Ikehara, Hiroki Ishikawa, Zhen Liu, Takeshi Hataguchi
  • Patent number: 10352927
    Abstract: It is intended to develop and provide a method for detecting a particular glycan-isoform rapidly and specifically by a small number of steps. The present invention provides a glycan-isoform detection method comprising quantifying an immune complex formed by the mixing of a test sample with a sugar chain non-reducing terminal residue-binding lectin and an antibody specifically binding to the protein moiety of the glycan-isoform, etc., comparing the obtained amount of the immune complex with the amount of a control immune complex obtained when a control sample is not mixed with the sugar chain non-reducing terminal residue-binding lectin or is mixed with a control protein, and determining the presence or absence of the glycan-isoform of interest in the test sample on the basis of the difference between these amounts.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: July 16, 2019
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Hisashi Narimatsu, Atsushi Kuno, Yuzuru Ikehara, Yasuhiro Hashimoto, Keiro Shirotani, Kiyomitsu Nara, Yoshinobu Kariya, Hiromi Ito, Kyoka Hoshi
  • Patent number: 10247733
    Abstract: It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-?1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase ?1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: April 2, 2019
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Maki Sogabe, Tomomi Kubota, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hiromichi Sawaki, Hayao Nakanishi, Toru Nakanishi
  • Publication number: 20190033203
    Abstract: Provided is an observation apparatus that observes tissues of an organism. The observation apparatus includes a generator that generates first data obtained by irradiating the tissues with a first infrared light with a first wavelength and second data obtained by irradiating the tissues with a second infrared light with a second wavelength being different from the first infrared light in an optical property value with respect to a water, and a comparison calculator that compares the first data with the second data to generate bodily fluid data that indicates a presence of a bodily fluid on a surface of the tissues.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE, NIKON CORPORATION
    Inventors: Yuzuru IKEHARA, Josaku SAKAKIMA
  • Publication number: 20190029090
    Abstract: In an imaging using fluorescence, for example, it is difficult to perform a surgery while a tumor part is directly confirmed in a bright operating room. A light irradiation system according to an embodiment performs an open/close control of a first eyesight of a first eyesight restrictor and a second eyesight of a second eyesight restrictor at every predetermined time interval. The light irradiation system controls a light-on of a light such that opening and closing timings of the first eyesight match a timing of a light amount control of a surgery lamp and opening and closing timings of the second eyesight match a timing of a light amount control of a fluorescence excitation light source (see FIG. 1).
    Type: Application
    Filed: September 21, 2018
    Publication date: January 24, 2019
    Applicants: National Institute of Advanced Industrial Science and Technology, Nikon Corporation
    Inventors: Yuzuru Ikehara, Susumu Makinouchi, Shunji Watanabe, Tetsuro Ishikawa
  • Patent number: 10156576
    Abstract: The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: December 18, 2018
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Hisashi Narimatsu, Jun Hirabayashi, Atsushi Kuno, Hideki Matsuzaki, Yuzuru Ikehara, Hiromi Ito, Yasuhiro Hashimoto, Keiro Shirotani, Satoshi Futakawa, Hajime Arai, Masakazu Miyajima, Kazuo Fujihara
  • Publication number: 20180288404
    Abstract: A technique that only and simply projects a video of a specific region on a body tissue is insufficient in some cases as an assistance technique for users in, for example, surgeries and pathological examinations. An image processing system includes an infrared light irradiating apparatus, an optical detector, a control apparatus, a display apparatus, and a projecting apparatus. The infrared light irradiating apparatus is configured to irradiate a biological tissue with infrared light. The optical detector is configured to detect light radiated from the biological tissue irradiated with the infrared light. The control apparatus is configured to create an image of the biological tissue using a detection result by the optical detector. The display apparatus is configured to display the created image. The projecting apparatus is configured to irradiate the biological tissue with first light.
    Type: Application
    Filed: March 9, 2018
    Publication date: October 4, 2018
    Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, NIKON CORPORATION
    Inventors: Yuzuru IKEHARA, Susumu Makinouchi, Tetsuro Ishikawa
  • Publication number: 20180202924
    Abstract: An imaging method includes: irradiating breast tissue with infrared light, detecting light in a narrow wavelength band selected from wavelength bands from 1400 nm or more to 1600 nm or less, among light radiated from the tissue irradiated with the infrared light, and generating, based on the detected light in the narrow wavelength band, an image to specify an area in the tissue containing breast cancer cell aggregation or breast cancer tissue.
    Type: Application
    Filed: March 16, 2018
    Publication date: July 19, 2018
    Applicants: JAPAN ORGANIZATION OF OCCUPATIONAL HEALTH AND SAFETY, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, NIKON CORPORATION
    Inventors: Kenichi HARIGAYA, Daisuke OZAKI, Yuzuru IKEHARA, Hiroki ISHIKAWA, Zhen LIU, Takeshi HATAGUCHI
  • Publication number: 20180106814
    Abstract: An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease.
    Type: Application
    Filed: November 10, 2017
    Publication date: April 19, 2018
    Inventors: Hisashi Narimatsu, Yuzuru Ikehara, Atsushi Kuno, Maki Sogabe, Yasuhito Tanaka, Masashi Mizokami, Kiyoaki Ito, Shunsuke Matsubara, Chikayuki Tsuruno, Youichi Takahama, Takashi Kagawa, Shinya Nagai
  • Patent number: 9816996
    Abstract: The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-?1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase ?1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: November 14, 2017
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Maki Sogabe, Tomomi Kubota, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hiromichi Sawaki, Hayao Nakanishi, Toru Nakanishi
  • Patent number: 9796761
    Abstract: The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: October 24, 2017
    Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE, GLYCOBIOMARKER LEADING INNOVATION CO., LTD.
    Inventors: Hisashi Narimatsu, Jun Hirabayashi, Yuzuru Ikehara, Takashi Angata, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Toshihide Shikanai, Maki Sogabe, Akira Togayachi, Makoto Ochou, Yasuhito Tanaka, Masashi Mizokami
  • Publication number: 20170283506
    Abstract: An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
    Type: Application
    Filed: June 12, 2017
    Publication date: October 5, 2017
    Applicants: National Institute of Advanced Industrial Science and Technology, Tokyo Medical University
    Inventors: Hisashi Narimatsu, Akira Togayachi, Yuzuru Ikehara, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Hideki Matsuzaki, Yoshitoshi Hirao, Jun Iwaki, Minako Abe, Masaharu Nomura, Masayuki Noguchi
  • Patent number: 9713242
    Abstract: A plasma treatment equipment includes: a plasma starting and stabilizing unit (A) having an insulating material such as a dielectric material having an elongated hole connecting to a plasma ejection portion, a triggering and discharge-stabilizing electrode, and an intense electric field electrode mounted thereon; and a plasma generating unit (B) including the insulating material having the elongated hole and a plasma generating electrode configured to perform main plasma generation at the time of operation, wherein the triggering and discharge-stabilizing electrode, the intense electric field electrode, and the plasma generating electrode are provided in such a manner that all the electrodes are not exposed and covered with the dielectric material for the entire space of one or more of the elongated hole which allows passage of gas from the upstream, starting of the plasma and generation of the plasma, and ejection of the plasma jet.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: July 18, 2017
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Hajime Sakakita, Yuzuru Ikehara, Satoru Kiyama
  • Patent number: 9696320
    Abstract: An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: July 4, 2017
    Assignees: National Institute of Advanced Industrial Science and Technology, Tokyo Medical University
    Inventors: Hisashi Narimatsu, Akira Togayachi, Yuzuru Ikehara, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Hideki Matsuzaki, Yoshitoshi Hirao, Jun Iwaki, Minako Abe, Masaharu Nomura, Masayuki Noguchi
  • Publication number: 20170107342
    Abstract: This technique provides a protein film production method which can form a protein film, with denaturation of protein being prevented. The protein film production method includes mixing a protein with an aqueous solvent, to thereby form an aqueous protein solution PAS1, and treating the aqueous protein solution PAS1 with plasma generated by a plasma generator 100. The plasma generated by the plasma generator 100 has a plasma density of 1×1013 cm?3 to 1×1015 cm?3.
    Type: Application
    Filed: November 15, 2016
    Publication date: April 20, 2017
    Applicants: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, KYORIN UNIVERSITY
    Inventors: Masaru HORI, Kenji ISHIKAWA, Yuzuru IKEHARA, Sanae IKEHARA, Hajime SAKAKITA, Yoshihiro AKIMOTO
  • Publication number: 20160187356
    Abstract: The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.
    Type: Application
    Filed: March 16, 2016
    Publication date: June 30, 2016
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Hisashi Narimatsu, Jun Hirabayashi, Atsushi Kuno, Hideki Matsuzaki, Yuzuru Ikehara, Hiromi Ito, Yasuhiro Hashimoto, Keiro Shirotani, Satoshi Futakawa, Hajime Arai, Masakazu Miyajima, Kazuo Fujihara
  • Publication number: 20160139039
    Abstract: An imaging system includes an infrared camera 10 that is sensitive to light beams having wavelengths in an infrared region, a lighting unit 20 that emits light beams having multiple wavelengths in an infrared region in a region including the wavelengths to which the infrared camera is sensitive, and a control unit 30 that controls capture of an image by the infrared camera 10 and emission of a light beam by the lighting unit 20.
    Type: Application
    Filed: November 25, 2015
    Publication date: May 19, 2016
    Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, NIKON CORPORATION
    Inventors: Yuzuru IKEHARA, Mutsuo OGURA, Susumu MAKINOUCHI
  • Patent number: 9254397
    Abstract: The present invention provides a plasma evaluation system and method for evaluating plasma, including: a treatment target material and a weak current measurement unit including a resistor unit and a differential amplifier, wherein the treatment target material is connected to the weak current measurement unit via a treatment target side measurement terminal, the resistor unit of the weak current measurement unit is connected to a ground side of a plasma generation current source, and the system and method evaluate plasma by receiving plasma generated by a plasma treatment equipment with the treatment target material, measuring a current by measuring a voltage across resistors of the resistor unit through the differential amplifier, and measuring an output voltage of the plasma generation power source.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: February 9, 2016
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Hajime Sakakita, Yuzuru Ikehara, Satoru Kiyama
  • Publication number: 20150338396
    Abstract: It is intended to develop and provide a method for detecting a particular glycan-isoform rapidly and specifically by a small number of steps. The present invention provides a glycan-isoform detection method comprising quantifying an immune complex formed by the mixing of a test sample with a sugar chain non-reducing terminal residue-binding lectin and an antibody specifically binding to the protein moiety of the glycan-isoform, etc., comparing the obtained amount of the immune complex with the amount of a control immune complex obtained when a control sample is not mixed with the sugar chain non-reducing terminal residue-binding lectin or is mixed with a control protein, and determining the presence or absence of the glycan-isoform of interest in the test sample on the basis of the difference between these amounts.
    Type: Application
    Filed: August 9, 2013
    Publication date: November 26, 2015
    Inventors: Hisashi NARIMATSU, Atsushi KUNO, Yuzuru IKEHARA, Yasuhiro HASHIMOTO, Keiro SHIROTANI, Kiyomitsu NARA, Yoshinobu KARIYA, Hiromi ITO, Kyoka HOSHI
  • Publication number: 20150293104
    Abstract: An object of the present invention is to develop and provide an epithelial ovarian cancer diagnosis marker with which epithelial ovarian cancer can be detected inexpensively, conveniently, and low invasively with high accuracy, and a method for determining the presence or absence of epithelial ovarian cancer using the marker. The present invention provides a glycoprotein having a glycan-linked asparagine residue at a particular site of the glycoprotein secreted from an epithelial ovarian cancer cell, or a fragment thereof having the glycan as an epithelial ovarian cancer diagnosis marker. The present invention also provides a method for determining the presence or absence of epithelial ovarian cancer using the glycoprotein.
    Type: Application
    Filed: July 12, 2012
    Publication date: October 15, 2015
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Hirofumi Nozaki, Takashi Ohkura, Atsushi Kuno, Maki Sogabe, Tomomi Kubota, Hiroyuki Kaji, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hayao Nakanishi, Toru Nakanishi